Article

More

Mold in Cannabis: Clinical Health Risks, Mycological Dangers, and Safety Guidelines

  • February 5, 2025

Inhaling or consuming mold-contaminated cannabis poses severe medical risks, ranging from acute respiratory inflammation and allergic sinusitis to life-threatening invasive pulmonary aspergillosis in immunocompromised individuals. Fungal spores and hazardous mycotoxins—including aflatoxins and ochratoxin A—frequently survive combustion and vaporization, making proper post-harvest curing and strict analytical laboratory testing essential. Board-certified family physician Dr. Benjamin Caplan provides an evidence-based clinical guide on identifying common cannabis molds, evaluating Certificate of Analysis (COA) safety thresholds, and protecting vulnerable patients.

More

The Truth About Cannabis Misinformation: 7 Common Myths Debunked by Clinical Science

  • January 27, 2025

Widespread cannabis misinformation—fueled by commercial dispensary marketing, anecdotal internet folklore, and historical medical training omissions—frequently misleads patients seeking safe, evidence-grounded therapeutic care. From the unverified commercial hype surrounding CBN as a primary sedative to obsolete Indica-versus-Sativa classifications, misleading narratives prevent patients from achieving predictable clinical outcomes. Board-certified family physician Dr. Benjamin Caplan debunks seven prevalent cannabis myths using clinical pharmacology, real-world registry observations, and modern endocannabinoid science.

More

Dr. Caplan, The Commonwealth Project, and the DEA Rescheduling Proceedings: Clinical Evidence and Policy Context

  • November 20, 2024

Selected as an accepted participant by the DEA Administrative Law Judge to represent geriatric care and older adult health needs during proposed federal Schedule III rescheduling proceedings, Dr. Benjamin Caplan advocates for evidence-based cannabis policy under the Controlled Substances Act. Although the formal administrative hearings did not convene following subsequent federal procedural delays, the clinical imperative to transition cannabis away from Schedule I remains urgent. This comprehensive regulatory brief examines the statutory criteria for accepted medical use, economic impacts for Medicare beneficiaries, and physician perspectives on federal reform.